{
  "id": 688735,
  "title": "GDUFA IV commitments: New onshoring incentives and meeting types for generic drugs",
  "url": "https://urgent.news/2026/08/12/gdufa-iv-commitments-new-onshoring-incentives-and-meeting-types-for",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-12T17:26:54.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/gdufa-iv-commitments-new-onshoring-incentives-and-meeting-types-for-generic-drugs/"
  },
  "original_language": "en",
  "account": null,
  "summary": "From 2028 to 2032, generic drug applicants will continue to see many of the same FDA review timelines as they did over the last five years, but new initiatives related to onshore manufacturing and new ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}